Related Experiment Video
Updated: Aug 11, 2026
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
Inactivation by the mitotic inhibitor NY 3170 of human cells in vitro
Abstract:
Inactivation of NHIK 3025 cells ny the mitotic inhibitor NY 3170 (1-propargyl-5-chloropyrimidin-2-one) was measured as loss of colony-forming ability. NY 3170 at a concentration of 0.15 nM allowed no formation of colonies after 12 days of continuous exposure to the drug. Metaphase arrest after treatment with NY 3170 was reversible if the drug was removed immediately after the onset of the arrest. When the cells were kept in mitosis by the presence of NY 3170, inactivation was complete after 8h incubation of mitotic cells with 0.4 nM NY 3170. Using synchronized cell populations, it was shown that mitosis is by far the most sensitive stage of the cell cycle to inactivation by NY 3170. This leads to the suggestion that there is a connection between the inactivating and the metaphase-arresting effect of this drug. The age response curves show that after mitosis the stages in order of decreasing sensitivity to NY3170 are: G2, late S, early S and G1. This is a similar age response to that reported for proliferating cells treated with bleomycin, whereas the mitotic inhibitors vincristine and vinblastine have shown qhite different age response curves.
Insights
The mitotic inhibitor NY 3170 effectively inactivates NHIK 3025 cells by arresting them in metaphase. Mitosis is the most sensitive cell cycle stage, with prolonged exposure leading to complete cell death.
Area of Science:
- Cell Biology
- Cancer Research
- Pharmacology
Background:
- The mitotic inhibitor NY 3170, chemically known as 1-propargyl-5-chloropyrimidin-2-one, targets cell division.
- Understanding the specific mechanisms and sensitivities of drugs like NY 3170 is crucial for developing effective cancer therapies.
Purpose of the Study:
- To investigate the inactivating effects of NY 3170 on NHIK 3025 cells.
- To determine the most sensitive stage of the cell cycle to NY 3170 treatment.
- To explore the relationship between metaphase arrest and cell inactivation by NY 3170.
Main Methods:
- Assessing cell inactivation by measuring loss of colony-forming ability after drug exposure.
- Utilizing synchronized cell populations to analyze cell cycle stage-specific sensitivity.
- Observing the reversibility of metaphase arrest upon drug removal.
Main Results:
- NY 3170 at 0.15 nM prevented colony formation after 12 days.
- Metaphase arrest induced by NY 3170 was reversible if the drug was removed promptly.
- Complete inactivation of mitotic cells occurred after 8 hours of exposure to 0.4 nM NY 3170.
- Mitosis was identified as the most sensitive cell cycle stage to NY 3170.
- Age response curves indicated decreasing sensitivity in the order: mitosis, G2, late S, early S, and G1.
Conclusions:
- NY 3170 effectively inactivates cells, with a strong correlation between its metaphase-arresting and cell-inactivating properties.
- The drug exhibits distinct cell cycle stage-specific toxicity, highlighting mitosis as a key target.
- The sensitivity profile of NY 3170 differs from other mitotic inhibitors like vincristine and vinblastine, suggesting a unique mechanism of action.
